Overview

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Treatments:
Rasagiline